Перфузионная Сцинтиграфия Сердца При Сахарном Диабете
Keywords:
Сахарный диабет, сердечно-сосудистые заболевания, ишемическая болезнь сердца, перфузия миокарда, сцинтиграфия
Abstract
Сахарный диабет (СД) является одним из важнейших факторов риска развития сердечно-сосудистых заболеваний (ССЗ). Наличие недостаточного достижения целевых уровней гликемии способствует не только развитию микрососудистых осложнений, но и отяжеляет течение ишемической болезни сердца (ИБС), гипертонической болезни (ГБ), частота встречаемости которых в два-четыре раза выше, чем у лиц, не страдающих диабетом. Аналогично, в геометрической прогрессии можно наблюдать и развитие сердечно-сосудистых событий (ССС) у больных с СД с высокой смертностью во всем мире. Кроме того, особое внимание необходимо уделять лицам, относящимся по шкале SCORE к субъектам с низким и средним риском.
References
1. A. Langer, M.R. Freeman, R.G. Josse, G. Steiner, P.W. Armstrong/ Detection of silent myocardial ischemia in diabetes mellitus (comments). Am J Cardiol, 67 (1991), pp. 1073-1078
2. American Diabetes Association . Standards of medical care in diabetes--2014. Diabetes care. 2014;37(Suppl 1):S14–80. 10.2337/dc14-S014
3. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes care. 2007;30(1):162–72. Epub 2006/12/29. 10.2337/dc07-9917 .
4. Cai X., Zhang Y., Li M., Wu J.H., Mai L., Li J. et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370:m2297. https://doi.org/10.1136/bmj.m2297.
5. Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Archives of neurology. 2011;68(10):1245–51. 10.1001/archneurol.2011.146 .
6. Caobelli F, Haaf P, Haenny G, Pfisterer M, Zellweger MJ; BARDOT Investigators. Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial. Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3512-3521. doi: 10.1007/s00259-021-05349-5. Epub 2021 Apr 21. PMID: 33884468; PMCID: PMC8440314.
7. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC, ESC Scientific Document Group 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323. doi: 10.1093/eurheartj/ehz486.
8. Dal Canto E, Ceriello A, Ryden L, et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_suppl):25–32. doi: 10.1177/2047487319878371.
9. E. Niakan, Y. Harati, L.A. Rolak, J.P. Comstock, R. Rokey. Silent myocardial infarction and diabetic cardiovascular autonomic neuropathy. Arch Intern Med, 146 (1986), pp. 2229-2230
10. Elhendy A, Schinkel A, Bax JJ, van Domburg RT, Poldermans D. Long-term prognosis after a normal exercise stress Tc-99m sestamibi SPECT study. J Nucl Cardiol. 2003;10:261–266. doi: 10.1016/S1071-3581(02)43219-9.
11. F.J. Wackers, L.H. Young, S.E. Inzucchi, et al.Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care, 27 (2004), pp. 1954-1961
12. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. The New England journal of medicine. 2003;348(5):383–93. Epub 2003/01/31. 10.1056/NEJMoa021778 .
13. Ghotbi A.A. Review: comparison of PET rubidium-82 with conventional SPECT myocardial perfusion imaging / A.A. Ghotbi, A. Kj^r, P. Hasbak // Clin. Physiol. Funct. Imaging. 2014. V.34. I.3. P. 163-170.
14. Greenland P, Alpert JS, Beller GA, et al.: 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122(25):2748–64. 10.1161/CIR.0b013e3182051bab
15. H. Miettinen, S. Lehto, V. Salomaa, et al. Impact of diabetes on mortality after the first myocardial infarction: the FINMONICA myocardial infarction register study group. Diabetes Care, 21 (1998), pp. 69-75
16. H.S. Cabin, W.C. Roberts. Quantitative comparison of extent of coronary narrowing and size of healed myocardial infarct in 33 necropsy patients with clinically recognized and in 28 with clinically unrecognized (“silent”) previous acute myocardial infarction. Am J Cardiol, 50 (1982), pp. 677-681.
17. Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico JA, Friedman J, Diamond GA. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation. 1998 Feb 17;97(6):535-43. doi: 10.1161/01.cir.97.6.535. Erratum in: Circulation 1998 Jul 14;98(2):190. PMID: 9494023.
18. Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol. 2000;36:355–365.
19. IDF Diabetes Atlas 2021. https://diabetesatlas.org/
20. J. Herlitz, B.W. Karlson, J. Lindqvist, M. Sjolin. Rate and mode of death during five years of follow-up among patients with acute chest pain with and without a history of diabetes mellitus. Diabetes Med, 15 (1998), pp. 308-314
21. Kang X, Berman DS, Lewin H, et al.: Comparative ability of myocardial perfusion single-photon emission computed tomography to detect coronary artery disease in patients with and without diabetes mellitus. Am Heart J. 1999;137(5):949–57. 10.1016/S0002-8703(99)70421-7
22. Leiter LA, Berard L, Bowering CK, Cheng AY, Dawson KG, Ekoe JM, et al. Type 2 diabetes mellitus management in Canada: is it improving? Canadian journal of diabetes. 2013;37(2):82–9. Epub 2013/09/28. 10.1016/j.jcjd.2013.02.055 .
23. M.J. Zellweger, R. Hachamovitch, X. Kang, et al. Prognostic relevance of symptoms versus objective evidence of coronary artery disease in diabetic patients/ Eur Heart J, 25 (2004), pp. 543-550
24. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(Suppl 2):S14–S21. doi: 10.1007/PL00002934.\
25. Prevalence and RIsk factors for Silent Myocardial ischemia (PRISM): A clinico observational study in patients of type 2 diabetes. D.S. Prasad a, Zubair Kabir b, K. Revathi Devi c, Pearline Suganthy Peter d, B.C. Das e. Indian Heart Journal. Volume 71, Issue 5, September–October 2019, Pages 400-405
26. Prieto-Vargas V, Bautista-Prez-Gavilan A, Lucio-Baez OE, Sierra-Poblete S, Gurrola-Luna H, et al. (2022) PET-Myocardial Perfusion Imaging in the Assessment of Coronary Artery Disease: the basics. Clin Res Trials 8: doi: 10.15761/CRT.1000363
27. R.W. Nesto, R.T. Phillips, K.G. Kett, et al. Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: assessment by exercise thallium scintigraphy/(published erratum appears in Ann Intern Med 1988;108:646) Ann Intern Med, 108 (1988), pp. 170-175
28. Rajagopalan N, Miller TD, Hodge DO, Frye RL, Gibbons RJ. Identifying high-risk asymptomatic diabetic patients who are candidates for screening stress single-photon emission computed tomography imaging. J Am Coll Cardiol 2005;45:43–9.
29. Rawshani A, Rawshani A, Franzen S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–644. doi: 10.1056/NEJMoa1800256.
30. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakso/ Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 339 (1998), pp. 229-234
31. T.Y. Goraya, C.L. Leibson, P.J. Palumbo, et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol, 40 (2002), pp. 946-953
32. Thomas GS, Miyamoto MI, Morello AP, 3rd, et al. Technetium 99m sestamibi myocardial perfusion imaging predicts clinical outcome in the community outpatient setting. The Nuclear Utility in the Community (NUC) Study. J Am Coll Cardiol. 2004;43:213–223. doi: 10.1016/j.jacc.2003.07.041.
33. Utility of screening for silent myocardial ischaemia in diabetes with an annual electrocardiogram. Liam O'Murchadha, Aoife M Egan, Kathleen Cahill, Carly Flynn, Dearbhail O'Flynn, James O'Neill, Seamus Sreenan, John H McDermott. Diabetic med journal/ Volume40, Issue3/ March 2023. e14983
34. van der Heijden AA, Van't Riet E, Bot SD, Cannegieter SC, Stehouwer CD, Baan CA, et al. Risk of a recurrent cardiovascular event in individuals with type 2 diabetes or intermediate hyperglycemia: the Hoorn Study. Diabetes care. 2013;36(11):3498–502. 10.2337/dc12-2691
35. Young LH, Wackers FJ, Chyun DA, et al.: Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009;301(15):1547–55. 10.1001/jama.2009.476
36. Диабет в Узбекистане: Клинико эпидемиологическая характеристика сахарного диабета (монография). Алиханова Н.М. Тураев Ф.Ф. Ташкент 2022й.
37. Остроумов Е.Н. Где нужна ядерная кардиология? / Е.Н. Остроумов // Российский кардиологический журнал. 2009. В.5. С. 4-9.
38. Перфузионная сцинтиграфия миокарда/ Д.В. Рыжкова. КАРДИОЛОГИЯ: новости, мнения, обучение №4 2016/ c76-76/
39. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakso/ Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 339 (1998), pp. 229-234
2. American Diabetes Association . Standards of medical care in diabetes--2014. Diabetes care. 2014;37(Suppl 1):S14–80. 10.2337/dc14-S014
3. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes care. 2007;30(1):162–72. Epub 2006/12/29. 10.2337/dc07-9917 .
4. Cai X., Zhang Y., Li M., Wu J.H., Mai L., Li J. et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370:m2297. https://doi.org/10.1136/bmj.m2297.
5. Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Archives of neurology. 2011;68(10):1245–51. 10.1001/archneurol.2011.146 .
6. Caobelli F, Haaf P, Haenny G, Pfisterer M, Zellweger MJ; BARDOT Investigators. Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial. Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3512-3521. doi: 10.1007/s00259-021-05349-5. Epub 2021 Apr 21. PMID: 33884468; PMCID: PMC8440314.
7. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC, ESC Scientific Document Group 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323. doi: 10.1093/eurheartj/ehz486.
8. Dal Canto E, Ceriello A, Ryden L, et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_suppl):25–32. doi: 10.1177/2047487319878371.
9. E. Niakan, Y. Harati, L.A. Rolak, J.P. Comstock, R. Rokey. Silent myocardial infarction and diabetic cardiovascular autonomic neuropathy. Arch Intern Med, 146 (1986), pp. 2229-2230
10. Elhendy A, Schinkel A, Bax JJ, van Domburg RT, Poldermans D. Long-term prognosis after a normal exercise stress Tc-99m sestamibi SPECT study. J Nucl Cardiol. 2003;10:261–266. doi: 10.1016/S1071-3581(02)43219-9.
11. F.J. Wackers, L.H. Young, S.E. Inzucchi, et al.Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care, 27 (2004), pp. 1954-1961
12. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. The New England journal of medicine. 2003;348(5):383–93. Epub 2003/01/31. 10.1056/NEJMoa021778 .
13. Ghotbi A.A. Review: comparison of PET rubidium-82 with conventional SPECT myocardial perfusion imaging / A.A. Ghotbi, A. Kj^r, P. Hasbak // Clin. Physiol. Funct. Imaging. 2014. V.34. I.3. P. 163-170.
14. Greenland P, Alpert JS, Beller GA, et al.: 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122(25):2748–64. 10.1161/CIR.0b013e3182051bab
15. H. Miettinen, S. Lehto, V. Salomaa, et al. Impact of diabetes on mortality after the first myocardial infarction: the FINMONICA myocardial infarction register study group. Diabetes Care, 21 (1998), pp. 69-75
16. H.S. Cabin, W.C. Roberts. Quantitative comparison of extent of coronary narrowing and size of healed myocardial infarct in 33 necropsy patients with clinically recognized and in 28 with clinically unrecognized (“silent”) previous acute myocardial infarction. Am J Cardiol, 50 (1982), pp. 677-681.
17. Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico JA, Friedman J, Diamond GA. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation. 1998 Feb 17;97(6):535-43. doi: 10.1161/01.cir.97.6.535. Erratum in: Circulation 1998 Jul 14;98(2):190. PMID: 9494023.
18. Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol. 2000;36:355–365.
19. IDF Diabetes Atlas 2021. https://diabetesatlas.org/
20. J. Herlitz, B.W. Karlson, J. Lindqvist, M. Sjolin. Rate and mode of death during five years of follow-up among patients with acute chest pain with and without a history of diabetes mellitus. Diabetes Med, 15 (1998), pp. 308-314
21. Kang X, Berman DS, Lewin H, et al.: Comparative ability of myocardial perfusion single-photon emission computed tomography to detect coronary artery disease in patients with and without diabetes mellitus. Am Heart J. 1999;137(5):949–57. 10.1016/S0002-8703(99)70421-7
22. Leiter LA, Berard L, Bowering CK, Cheng AY, Dawson KG, Ekoe JM, et al. Type 2 diabetes mellitus management in Canada: is it improving? Canadian journal of diabetes. 2013;37(2):82–9. Epub 2013/09/28. 10.1016/j.jcjd.2013.02.055 .
23. M.J. Zellweger, R. Hachamovitch, X. Kang, et al. Prognostic relevance of symptoms versus objective evidence of coronary artery disease in diabetic patients/ Eur Heart J, 25 (2004), pp. 543-550
24. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(Suppl 2):S14–S21. doi: 10.1007/PL00002934.\
25. Prevalence and RIsk factors for Silent Myocardial ischemia (PRISM): A clinico observational study in patients of type 2 diabetes. D.S. Prasad a, Zubair Kabir b, K. Revathi Devi c, Pearline Suganthy Peter d, B.C. Das e. Indian Heart Journal. Volume 71, Issue 5, September–October 2019, Pages 400-405
26. Prieto-Vargas V, Bautista-Prez-Gavilan A, Lucio-Baez OE, Sierra-Poblete S, Gurrola-Luna H, et al. (2022) PET-Myocardial Perfusion Imaging in the Assessment of Coronary Artery Disease: the basics. Clin Res Trials 8: doi: 10.15761/CRT.1000363
27. R.W. Nesto, R.T. Phillips, K.G. Kett, et al. Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: assessment by exercise thallium scintigraphy/(published erratum appears in Ann Intern Med 1988;108:646) Ann Intern Med, 108 (1988), pp. 170-175
28. Rajagopalan N, Miller TD, Hodge DO, Frye RL, Gibbons RJ. Identifying high-risk asymptomatic diabetic patients who are candidates for screening stress single-photon emission computed tomography imaging. J Am Coll Cardiol 2005;45:43–9.
29. Rawshani A, Rawshani A, Franzen S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–644. doi: 10.1056/NEJMoa1800256.
30. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakso/ Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 339 (1998), pp. 229-234
31. T.Y. Goraya, C.L. Leibson, P.J. Palumbo, et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol, 40 (2002), pp. 946-953
32. Thomas GS, Miyamoto MI, Morello AP, 3rd, et al. Technetium 99m sestamibi myocardial perfusion imaging predicts clinical outcome in the community outpatient setting. The Nuclear Utility in the Community (NUC) Study. J Am Coll Cardiol. 2004;43:213–223. doi: 10.1016/j.jacc.2003.07.041.
33. Utility of screening for silent myocardial ischaemia in diabetes with an annual electrocardiogram. Liam O'Murchadha, Aoife M Egan, Kathleen Cahill, Carly Flynn, Dearbhail O'Flynn, James O'Neill, Seamus Sreenan, John H McDermott. Diabetic med journal/ Volume40, Issue3/ March 2023. e14983
34. van der Heijden AA, Van't Riet E, Bot SD, Cannegieter SC, Stehouwer CD, Baan CA, et al. Risk of a recurrent cardiovascular event in individuals with type 2 diabetes or intermediate hyperglycemia: the Hoorn Study. Diabetes care. 2013;36(11):3498–502. 10.2337/dc12-2691
35. Young LH, Wackers FJ, Chyun DA, et al.: Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009;301(15):1547–55. 10.1001/jama.2009.476
36. Диабет в Узбекистане: Клинико эпидемиологическая характеристика сахарного диабета (монография). Алиханова Н.М. Тураев Ф.Ф. Ташкент 2022й.
37. Остроумов Е.Н. Где нужна ядерная кардиология? / Е.Н. Остроумов // Российский кардиологический журнал. 2009. В.5. С. 4-9.
38. Перфузионная сцинтиграфия миокарда/ Д.В. Рыжкова. КАРДИОЛОГИЯ: новости, мнения, обучение №4 2016/ c76-76/
39. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakso/ Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 339 (1998), pp. 229-234
Published
2023-04-06
How to Cite
М., А. Н., Г. , Д. Д., Б., М. Ч., Б., Н. Д., Х., У. Л., Ф. , А. Ф., А. , Т. Ф., & С., Н. Н. (2023). Перфузионная Сцинтиграфия Сердца При Сахарном Диабете. Central Asian Journal of Medical and Natural Science, 4(2), 345-353. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/1424
Section
Articles
